MedTrace Logo

The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)

NCT04818983 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 470

Last updated 2024-04-02

No results posted yet for this study

Summary

This study is implemented in association with the study "J-TAIL-2" ; prospective multicenter observational study of atezolizumab in patients with unresectable, locally advanced or metastatic non-small cell lung cancer, UMIN study ID: UMIN000041263, to evaluate biomarkers for selection of appropriate patients in treatment with atezolizumab combination therapy.

Conditions

Sponsors & Collaborators

  • Japan Lung Cancer Society

    collaborator OTHER

  • Chugai Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Akihiko GENMA · Nippon Medical School

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-07
Primary Completion
2023-02-03
Completion
2023-02-03

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04818983 on ClinicalTrials.gov